NVO

Novo Nordisk A/S

research_scan theme='longevity-aging'; value_chain_position='pure-play'; Wegovy / Ozempic / Rybelsus franchise with the SELECT-trial cardiovascular outcome expanding Medicare coverage politics. Catalent integration via Novo Holdings 2024 transaction backfills fill-finish capacity bottleneck and represents the cleanest sovereign-adjacent biotech transaction extant. Less politically exposed than LLY for IRA cycle 3 since the franchise is Danish-domiciled and Wegovy's obesity-only Medicare-line size is smaller than Mounjaro's.